IP Library Patent Application 15221265
Patent Application
App. No. 15/221,265

Production of Lentiviral Vectors

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/221,265
Abstract

A high-volume gene therapy vector manufacturing process which produces a recombinant gene therapy vector which is able to transform host cells even when they are not dividing.

Claims (28)

1 . A method comprising:

a. Transducing a mammalian cell with a baculovirus to make a transduced mammalian producer cell; and then

b. Culturing said transduced mammalian producer cell in culture media, and harvesting from said transduced mammalian producer cell and/or culture media a second virus having a therapeutic transgene.

2 . The method of claim 1 , wherein said harvesting comprises harvesting at about 144 hours after said transduction.

3 . The method of claim 1 , wherein said second virus is derived from a virus which in its wild state has a single-stranded genome.

4 . The method of claim 1 , wherein said second virus is able to transduce a human cell which is not actively dividing.

5 . The method of claim 1 , wherein said second virus is replication deficient.

6 . The method of claim 1 , wherein said second virus can integrate in host genome at specific site and can produce stable long-term expression.

7 . The method of claim 1 , wherein said second virus is non-immunogenic.

8 . A recombinant baculovirus having at least one nucleic acid sequence coding for a second virus derived from a virus which in its wild state has a single stranded genome, said second virus being replication-deficient and having a therapeutic transgene.

9 . The recombinant baculovirus of claim 8 , wherein said second virus is able to transduce a human cell which is not actively dividing.

10 . The recombinant baculovirus of claim 8 , wherein said second virus can integrate in the human genome and can produce stable long-term expression in a transduced human cell.

11 . A method comprising:

a. Obtaining the recombinant baculovirus of claim 8 ; and then

b. Transducing a mammalian producer cell with said recombinant baculovirus to make a transduced mammalian producer cell; and then

c. Culturing said transduced mammalian producer cell in culture media, and harvesting said second virus from said transduced mammalian producer cell and/or culture media.

12 . A viral vector able to transfect a human cell which is not actively dividing, said viral vector produced by a mammalian producer cell transduced with a recombinant baculovirus.

13 . The viral vector of claim 12 , wherein said viral vector has a therapeutic transgene.

14 . The viral vector of claim 12 , said viral vector comprises virus derived from a virus which in its wild state has a single stranded genome.

15 . A method comprising:

a. Obtaining the viral vector of claim 12 ; and

b. Transducing a human patient's cells with said viral vector.

16 . A method comprising:

a. Obtaining the viral vector of claim 13 ; and

b. Transducing a human patient's cells with said viral vector.

17 . A method comprising:

a. Obtaining the viral vector of claim 14 ; and

b. Transducing a human patient's cells with said viral vector.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2017
From: AIRENNE, KARI J.; LESCH, HANNA P.; YLA-HERTTUALA, SEPPO
To: ARK THERAPEUTICS LTD.
Reel/Frame 040901/0241 →
CHANGE OF NAME Recorded Jan 9, 2017
From: FINVECTOR VISION THERAPIES LTD
To: TRIZELL LTD
Reel/Frame 040901/0335 →
CHANGE OF NAME Recorded Jan 9, 2017
From: ARK THERAPEUTICS LTD.
To: FINVECTOR VISION THERAPIES LTD
Reel/Frame 041304/0595 →